Abstract
Itraconazole is a triazole compound which, following several clinical trials, has begun to be used for therapy of mycotic infections. This new drug, with a broad-spectrum antifungal activity, can be orally administered. The Authors studied the in vitro susceptibility to amphotericin B and itraconazole of the following clinical isolates of pathogenic yeasts: 100 Candida albicans, 20 C. tropicalis, 20 C. parapsilosis, 8 C. guilliermondii, 6 C. pseudotropicalis, 24 Torulopsis glabrata and 16 Cryptococcus neoformans. Serial two-fold dilutions, from 100 μg/ml to 0.04 μg/ml, of each drug were prepared in Yeast Nitrogen Base + Glucose 5%, after dissolving the itraconazole in dimethylsulfoxide (DMSO) and amphotericin B in 5% glucose solution. Amphotericin B (MIC90: 3.12 μg/ml) was found to have an average in vitro MIC six-fold lower than itraconazole (MIC90: 25 μg/ml). Thus, even though itraconazole is active, amphotericin B remains one of the most effective of the antifungal drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 31-34 |
| Number of pages | 4 |
| Journal | Mycopathologia |
| Volume | 106 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Apr 1989 |
Fingerprint
Keywords
- amphotericin B
- itraconazole
- susceptibility testing
- yeast infections
ASJC Scopus subject areas
- Plant Science
- Agricultural and Biological Sciences (miscellaneous)
Cite this
Itraconazole vs amphotericin B : in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts. / Lombardi, G.; Gramegna, G.; Cavanna, C.; Poma, G.; Marangoni, E.; Michelone, G.
In: Mycopathologia, Vol. 106, No. 1, 04.1989, p. 31-34.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Itraconazole vs amphotericin B
T2 - in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts
AU - Lombardi, G.
AU - Gramegna, G.
AU - Cavanna, C.
AU - Poma, G.
AU - Marangoni, E.
AU - Michelone, G.
PY - 1989/4
Y1 - 1989/4
N2 - Itraconazole is a triazole compound which, following several clinical trials, has begun to be used for therapy of mycotic infections. This new drug, with a broad-spectrum antifungal activity, can be orally administered. The Authors studied the in vitro susceptibility to amphotericin B and itraconazole of the following clinical isolates of pathogenic yeasts: 100 Candida albicans, 20 C. tropicalis, 20 C. parapsilosis, 8 C. guilliermondii, 6 C. pseudotropicalis, 24 Torulopsis glabrata and 16 Cryptococcus neoformans. Serial two-fold dilutions, from 100 μg/ml to 0.04 μg/ml, of each drug were prepared in Yeast Nitrogen Base + Glucose 5%, after dissolving the itraconazole in dimethylsulfoxide (DMSO) and amphotericin B in 5% glucose solution. Amphotericin B (MIC90: 3.12 μg/ml) was found to have an average in vitro MIC six-fold lower than itraconazole (MIC90: 25 μg/ml). Thus, even though itraconazole is active, amphotericin B remains one of the most effective of the antifungal drugs.
AB - Itraconazole is a triazole compound which, following several clinical trials, has begun to be used for therapy of mycotic infections. This new drug, with a broad-spectrum antifungal activity, can be orally administered. The Authors studied the in vitro susceptibility to amphotericin B and itraconazole of the following clinical isolates of pathogenic yeasts: 100 Candida albicans, 20 C. tropicalis, 20 C. parapsilosis, 8 C. guilliermondii, 6 C. pseudotropicalis, 24 Torulopsis glabrata and 16 Cryptococcus neoformans. Serial two-fold dilutions, from 100 μg/ml to 0.04 μg/ml, of each drug were prepared in Yeast Nitrogen Base + Glucose 5%, after dissolving the itraconazole in dimethylsulfoxide (DMSO) and amphotericin B in 5% glucose solution. Amphotericin B (MIC90: 3.12 μg/ml) was found to have an average in vitro MIC six-fold lower than itraconazole (MIC90: 25 μg/ml). Thus, even though itraconazole is active, amphotericin B remains one of the most effective of the antifungal drugs.
KW - amphotericin B
KW - itraconazole
KW - susceptibility testing
KW - yeast infections
UR - http://www.scopus.com/inward/record.url?scp=0024399245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024399245&partnerID=8YFLogxK
U2 - 10.1007/BF00436923
DO - 10.1007/BF00436923
M3 - Article
C2 - 2549421
AN - SCOPUS:0024399245
VL - 106
SP - 31
EP - 34
JO - Mycopathologia
JF - Mycopathologia
SN - 0301-486X
IS - 1
ER -